PRCT · PROCEPT BioRobotics Corp
$17.16
+0.14 (+0.82%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$985.11M
Shares
57.27M
Volume · Oct 2
1.24M
Avg daily vol (3M)
1.47M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.16
Open$17.19
Day$16.95–17.91
52W close$16.69–36.95
Avg vol 30d1.3M
Short int7.4M · 13.0% float · 5.6d
Short vol47%
Last earningsAug 4, 2026
DataSep 2021–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$337.34M
Trailing 12 months
Net income (TTM)
−$109.76M
Trailing 12 months
Revenue growth YoY
+19.3%
Year over year
Operating margin
-33.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.9%
Year over year · more shares
Price change (1Y)
-50.7%
Trailing year
Short interest
13.0%
Latest settlement · 5.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−13%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−27%
trailing
YTD return
−45%
this year
Relative strength
−39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $25 — 200d above 50d
Institutional flow
Accumulating
1 of 256 funds reported for Sep 30 · net +839 sh shares
Insider flow
Accumulating
Net +$476.5K over 90 days · 75% sells
Short interest
Rising
12.99% of float · ▲ +2.6% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
256 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
Gross margin
64%
expanding
EPS growth
+2%
Y/Y
Free cash flow
$-58.3M
Balance sheet
$234.9M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Revenue
· full year 2026
Initiated
$390M – $410M
prior FY $308.05M
midpoint +29.8% Y/Y
Guided vs delivered
· last 4 settled
Revenue
full year 2024
guided $217M
$224.5M
Beat +3.5%
Revenue
full year 2023
guided $133.5M
$136.19M
Beat +2.0%
Total revenue
fourth quarter
guided $8.7M – $9M
$10.14M
Beat +14.6%
Revenues
full year 2021
guided $33M – $33.3M
$34.47M
Beat +4.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $25 — 200d above 50d
Institutional flow
Accumulating
1 of 256 funds reported for Sep 30 · net +839 sh shares
Insider flow
Accumulating
Net +$476.5K over 90 days · 75% sells
Short interest
Rising
12.99% of float · ▲ +2.6% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
256 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $17
Now $17 · 2%
Range high $37
vs 200-day avg -31%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRCT
this stock
PROCEPT BioRobotics Corp
|
$985.11M | -45.5% | +37.2% | — | 13.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRCT | -0.2% | -19.7% | -26.9% | -5.8% | -45.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | 0.0% | -19.2% | -39.0% | -6.7% | -58.3% |